Literature DB >> 8494727

Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice.

Y Ohe1, E R Podack, K J Olsen, Y Miyahara, K Miura, H Saito, Y Koishihara, Y Ohsugi, T Ohira, K Nishio.   

Abstract

HuIL-6 cDNA, cloned into a neomycin resistant conferring expression vector, BMGNeo, was transfected into Lewis Lung Carcinoma (LLC) cells. LLC cells (5 x 10(6) ml-1) transfected with IL-6 cDNA (LLC-IL6) secreted IL-6 into the culture supernatant at a concentration of 9.9 ng ml-1 within 48 h. When 1,000,000 of untransfected LLC, BMGNeo vector transfected LLC (LLC-Neo) or LLC-IL6 cells were transplanted into C57BL/6 mice subcutaneously, the mean +/- s.d. of survival times of these mice were 33.3 +/- 9.7, 34.3 +/- 7.1 and 17.0 +/- 3.1 days, respectively. The survival time of LLC-IL6 cells transplanted mice was significantly shorter than that of LLC (P < 0.01) or LLC-Neo (P < 0.01) cells transplanted mice without a measurable difference of tumour size. Plasma concentration of IL-6 steadily increased in LLC-IL6 transplanted mice. Body weight and serum albumin were significantly lower in LLC-IL6 transplanted mice than in LLC transplanted mice. Mouse IL-1 alpha and mouse TNF-alpha were not detected in the plasma of LLC-IL6 transplanted mice. These data suggested that secretion of IL-6 from LLC cells was unable to alter net tumour growth rate but rather caused a state similar to cachexia without detectable increase of IL-1 alpha and TNF-alpha in the plasma. This state may be responsible for the shortened survival of LLC-IL6 tumour-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494727      PMCID: PMC1968462          DOI: 10.1038/bjc.1993.174

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Stimulation of thrombopoiesis in mice by human recombinant interleukin 6.

Authors:  R J Hill; M K Warren; J Levin
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

2.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

Authors:  A L Asher; J J Mulé; A Kasid; N P Restifo; J C Salo; C M Reichert; G Jaffe; B Fendly; M Kriegler; S A Rosenberg
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

3.  Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice.

Authors:  K Black; I R Garrett; G R Mundy
Journal:  Endocrinology       Date:  1991-05       Impact factor: 4.736

4.  Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody.

Authors:  M Mizuno; J Yoshida; K Sugita; I Inoue; H Seo; Y Hayashi; T Koshizaka; K Yagi
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

5.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

Authors:  B Gansbacher; R Bannerji; B Daniels; K Zier; K Cronin; E Gilboa
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

6.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

Authors:  R Bataille; M Jourdan; X G Zhang; B Klein
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.

Authors:  J Gelin; L L Moldawer; C Lönnroth; B Sherry; R Chizzonite; K Lundholm
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  IgG1 plasmacytosis in interleukin 6 transgenic mice.

Authors:  S Suematsu; T Matsuda; K Aozasa; S Akira; N Nakano; S Ohno; J Miyazaki; K Yamamura; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.

Authors:  M P Colombo; G Ferrari; A Stoppacciaro; M Parenza; M Rodolfo; F Mavilio; G Parmiani
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

10.  The in vivo anti-tumor effect of human recombinant interleukin-6.

Authors:  M Kitahara; S Kishimoto; T Hirano; T Kishimoto; M Okada
Journal:  Jpn J Cancer Res       Date:  1990-10
View more
  18 in total

1.  Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.

Authors:  A Miller; L McLeod; S Alhayyani; A Szczepny; D N Watkins; W Chen; P Enriori; W Ferlin; S Ruwanpura; B J Jenkins
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

2.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.

Authors:  J S Goydos; A M Brumfield; E Frezza; A Booth; M T Lotze; S E Carty
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

3.  Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation.

Authors:  T Ohira; K Nishio; Y Ohe; H Arioka; M Nishio; Y Funayama; H Ogasawara; M Fukuda; K Yazawa; H Kato; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  The relationship between weight loss and interleukin 6 in non-small-cell lung cancer.

Authors:  H R Scott; D C McMillan; A Crilly; C S McArdle; R Milroy
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

5.  In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.

Authors:  T Ohira; Y Ohe; Y Heike; E R Podack; K J Olsen; K Nishio; M Nishio; Y Miyahara; Y Funayama; H Ogasawara
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 7.  Understanding cachexia in the context of metastatic progression.

Authors:  Anup K Biswas; Swarnali Acharyya
Journal:  Nat Rev Cancer       Date:  2020-03-31       Impact factor: 60.716

8.  Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.

Authors:  X Cao; W Zhang; S Gu; Y Yu; Q Tao; T Ye
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Noelia Kunzevitzky; Denis C Guttridge; Sawsan Khuri; Leonidas G Koniaris; Teresa A Zimmers
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

10.  Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect.

Authors:  J Kurebayashi; S Yamamoto; T Otsuki; H Sonoo
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.